Standards of care for treatment of recurrent glioblastoma—are we there yet?
German Cancer Research Center · University of Zurich · +6 more institutions
Abstract
Newly diagnosed glioblastoma is now commonly treated with surgery, if feasible, or biopsy, followed by radiation plus concomitant and adjuvant temozolomide. The treatment of recurrent glioblastoma continues to be a moving target as new therapeutic principles enrich the standards of care for newly diagnosed disease. We reviewed PubMed and American Society of Clinical Oncology abstracts from January 2006 to January 2012 to identify clinical trials investigating the treatment of recurrent or progressive glioblastoma with nitrosoureas, temozolomide, bevacizumab, and/or combinations of these agents. At recurrence, a minority of patients are eligible for second surgery or reirradiation, based on appropriate patient…
Citation impact
- FWCI
- 15.52
- Percentile
- 100%
- References
- 128
Authors
4- MWMichael WellerCorresponding
German Cancer Research Center, University of Zurich, University of Toronto, UCLA Health, Heidelberg University, University Hospital of Zurich, Sunnybrook Health Science Centre, Health Sciences Centre
- TFTimothy F. Cloughesy
University of Toronto, Sunnybrook Health Science Centre, University Hospital of Zurich, German Cancer Research Center, Health Sciences Centre, UCLA Health, Heidelberg University
- JPJames Perry
German Cancer Research Center, Heidelberg University, Sunnybrook Health Science Centre, Health Sciences Centre, University of Toronto, UCLA Health, University Hospital of Zurich
- WWWolfgang Wick
UCLA Health, German Cancer Research Center, Heidelberg University, University Hospital of Zurich, Sunnybrook Health Science Centre, Health Sciences Centre, University of Toronto
Topics & keywords
- Temozolomide
- Bevacizumab
- Medicine
- Oncology
- Glioblastoma
- Adjuvant
- Concomitant
- Clinical trial
- Good health and well-being